Stock Analysis on Net

Shockwave Medical Inc. (NASDAQ:SWAV)

This company has been moved to the archive! The financial data has not been updated since May 6, 2024.

Common-Size Income Statement 
Quarterly Data

Shockwave Medical Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel
3 months ended: Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Product revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Revenue 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Cost of product revenue -12.89 -12.47 -13.18 -13.59 -13.08 -12.15 -13.61 -13.86 -13.77 -15.04 -16.80 -17.77 -24.74 -28.49 -26.94 -34.92 -37.18 -38.80 -38.83 -41.28 -42.26
Cost of revenue -12.89% -12.47% -13.18% -13.59% -13.08% -12.15% -13.61% -13.86% -13.77% -15.04% -16.80% -17.77% -24.74% -28.49% -26.94% -34.92% -37.18% -38.80% -38.83% -41.28% -42.26%
Gross profit 87.11% 87.53% 86.82% 86.41% 86.92% 87.85% 86.39% 86.14% 86.23% 84.96% 83.20% 82.23% 75.26% 71.51% 73.06% 65.08% 62.82% 61.20% 61.17% 58.72% 57.74%
Research and development -20.32 -20.85 -21.25 -20.44 -16.75 -16.47 -15.36 -17.19 -18.18 -17.48 -21.08 -21.13 -32.22 -39.81 -40.28 -78.76 -78.24 -70.39 -73.84 -69.18 -102.96
Sales and marketing -34.04 -33.10 -30.59 -31.49 -33.53 -30.16 -32.04 -33.55 -38.41 -39.43 -43.58 -45.99 -75.21 -72.35 -69.52 -108.94 -68.51 -67.04 -72.28 -69.53 -80.77
General and administrative -13.36 -12.26 -11.53 -16.50 -11.92 -11.76 -10.99 -10.90 -13.23 -11.44 -14.22 -15.43 -22.65 -29.19 -28.64 -52.48 -40.96 -31.10 -30.33 -32.41 -41.28
Operating expenses -67.73% -66.20% -63.37% -68.44% -62.20% -58.39% -58.40% -61.65% -69.82% -68.35% -78.88% -82.55% -130.08% -141.36% -138.44% -240.18% -187.70% -168.53% -176.45% -171.11% -225.01%
Income (loss) from operations 19.38% 21.32% 23.45% 17.97% 24.72% 29.46% 27.99% 24.49% 16.42% 16.61% 4.32% -0.32% -54.82% -69.85% -65.38% -175.10% -124.89% -107.33% -115.28% -112.40% -167.27%
Income (loss) from equity method investment 0.33 -0.08 -0.39 -0.08 -0.51 -0.74 0.07 -1.21 -0.05 -0.50 -0.52 0.00 -17.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest income 5.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Interest expense -1.35 -1.45 -1.35 -0.45 -0.39 -0.67 -0.24 -0.25 -0.32 -0.36 -0.25 -0.57 -0.98 -1.39 -1.60 -2.97 -1.82 -1.38 -2.21 -2.50 -3.37
Change in fair value of warrant liability 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.38
Other income (expense), net -1.14 7.54 2.53 0.88 1.48 2.96 -1.08 -1.22 -0.33 -0.25 -0.43 0.26 -0.74 1.38 1.11 2.14 3.32 5.77 3.40 9.12 3.04
Net income (loss) before taxes 22.85% 27.32% 24.23% 18.32% 25.29% 31.00% 26.74% 21.81% 15.72% 15.50% 3.11% -0.63% -73.85% -69.85% -65.87% -175.94% -123.39% -102.94% -114.10% -105.77% -175.98%
Income tax (provision) benefit 2.44 -5.50 -5.43 -2.30 -1.00 66.83 -0.09 -0.64 -0.21 -0.13 -0.12 -0.13 -0.14 -0.03 -0.15 -0.20 -0.15 -0.08 -0.23 -0.18 -0.10
Net income (loss) 25.29% 21.83% 18.81% 16.02% 24.29% 97.84% 26.65% 21.17% 15.51% 15.37% 2.99% -0.76% -73.98% -69.88% -66.01% -176.14% -123.54% -103.02% -114.33% -105.95% -176.08%

Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).


Gross Profit Margin Trends
The gross profit margin improved steadily over the analyzed periods, rising from 57.74% in March 2019 to a range around 87% by early 2024. This increase reflects a consistent reduction in the cost of product revenue relative to total revenue, declining from approximately 42% to around 13%, indicating enhanced operational efficiency or favorable cost management in production.
Operating Expenses Analysis
Operating expenses as a percentage of revenue exhibited a notable decline from more than 225% in early 2019 to approaching 68% by the end of 2023 and into 2024. Research and development expenses, which initially were exceptionally high at over 100% and frequently above 70%, have been markedly reduced to stabilize near 20%. Sales and marketing, despite fluctuations, show a downward trend from around 80% to about 34%, while general and administrative costs decreased from roughly 41% to near 13%. These trends collectively indicate a significant improvement in cost control across major expense categories.
Profitability and Income Trends
Operational losses significantly narrowed over the period, shifting from a loss of around 167% of revenue in early 2019 to positive operating income by mid-2021, sustaining profitability thereafter, with operating income stabilizing between 20% and 30% of revenue. Correspondingly, net income transitioned from substantial losses near -176% to positive territory, reaching approximately 25% of revenue by the first quarter of 2024. This turning point signals enhanced operational leverage and profitability.
Other Financial Items and Their Impact
Income (loss) from equity method investments remained relatively small and variable, generally under 1% of revenue and occasionally negative, having minimal overall impact on net results. Interest expense showed a declining trend from over 3% to near 1.3%, contributing modestly to income improvement. Interest income appeared only in the latest period at 5.63% of revenue, suggesting new income sources. Other income (expense), net, fluctuated moderately with occasional positive spikes, but without consistent directional impact. The income tax provision varied but notably included a large positive benefit in late 2022, which temporarily inflated net income during that period.
Summary of Financial Health
Overall, the financial data reveals a company moving from significant losses and very high operating expenses towards sustained profitability and efficient cost management. Gross margin expansion alongside lower operating expenses underlines improved operational efficiency. The gradual reduction of losses followed by positive net income highlights successful execution of business strategies and emerging financial stability by the most recent quarters.